switching from semaglutide to tirzepatide results Switch Switching Between Semaglutide and Tirzepatide:

Merino B, Quesada I, Hernndez-Cascales J (2015) Glucagon Increases beating rate but not contractility in rat right atrium

Advanced-phase studies (Phase 3 and 4) continue to support its core applications in diabetes and obesity, but early research into its use for neurodegenerative and liver-related disorders presents opportunities for future market growth

Highly recommend Angela if you are looking for subtle, refined, and long-lasting results

Patients should report suspected adverse reactions via the MHRA Yellow Card Scheme

In the OASIS 4 phase 3 trial, once-daily oral semaglutide at a dose of 25 mg resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity

If you're having surgery, it's essential to let your anaesthetist know you're on a GLP-1 medication, as they slow down digestion and may increase your risk of complications under anaesthetic